{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:47:28Z","timestamp":1793144848104,"version":"4.5.0"},"reference-count":101,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"unspecified","delay-in-days":62,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Zogenix GmbH, Germany"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2020,10,2]]},"DOI":"10.1080\/14737175.2020.1801423","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:17:03Z","timestamp":1597796223000},"page":"1065-1079","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":60,"title":["Therapeutic advances in Dravet syndrome: a targeted literature review"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6288-9915","authenticated-orcid":false,"given":"Adam","family":"Strzelczyk","sequence":"first","affiliation":[{"name":"Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery, Goethe-University Frankfurt, Frankfurt am Main, Germany"},{"name":"LOEWE Center for Personalized and Translational Epilepsy Research (CePTER), Goethe-University Frankfurt, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1545-7364","authenticated-orcid":false,"given":"Susanne","family":"Schubert-Bast","sequence":"additional","affiliation":[{"name":"Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery, Goethe-University Frankfurt, Frankfurt am Main, Germany"},{"name":"LOEWE Center for Personalized and Translational Epilepsy Research (CePTER), Goethe-University Frankfurt, Frankfurt am Main, Germany"},{"name":"Department of Neuropediatrics, Goethe-University Frankfurt, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,8,16]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.21366.1"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13709"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2017.01.025"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.02994.x"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws198"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03001.x"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0511-y"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2016.09.007"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12927"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.12709"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-1807"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03129.x"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.13591"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.01.003"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16099"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2018.12.018"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.12.034"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2019.02.014"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16334"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2011.03967.x"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.06.021"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00666-8"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14191"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2018.1552937"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2019.55.3.2909248"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01204-y"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.08.021"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2019.1605904"},{"key":"cit0029","unstructured":"DIACOMIT. Prescribing Information. [cited 2020 Mar]. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206709s000,207223s000lbl.pdf"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03157-3"},{"key":"cit0031","unstructured":"European Medicines Agency. Diacomit: EPAR - Scientific Discussion. 2009. [cited 2020 Mar]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/diacomit-epar-scientific-discussion_en.pdf"},{"key":"cit0032","unstructured":"FDA. DIACOMIT. Clinical Review. [cited 2020 Mar]. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/206709Orig1s000%2c207223Orig1s000MedR.pdf"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14536"},{"key":"cit0034","unstructured":"DIACOMIT. Summary of Product Characteristics. [cited 2020 Mar]. Available from https:\/\/www.medicines.org.uk\/emc\/product\/10300\/smpc"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.13704"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16363"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1177\/0883073818811538"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2016.05.012"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12611"},{"key":"cit0040","first-page":"10","volume":"22","author":"Gray RA","year":"2020","journal-title":"Epileptic Disord"},{"key":"cit0041","unstructured":"EPIDIOLEX. Prescribing Information. [cited 2020 Mar]. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210365lbl.pdf"},{"key":"cit0042","unstructured":"European Medicines Agency. Epidyolex. [cited 2020 Mar]. Available from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/epidyolex"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611618"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0073"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14628"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.106989"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32500-0"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.4113"},{"key":"cit0049","unstructured":"FINTEPLA. Prescribing Information. [cited 2020 Mar]. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212102s000lbl.pdf"},{"key":"cit0050","unstructured":"Lagae L, Sullivan J, Nabbout R, et al. Fenfluramine HCL (Fintepla\u00ae) provides long-term clinically meaningful reduction in seizure frequency: results of an open-label extension study. 72nd American Epilepsy Society Annual Meeting. 2018 Dec. Abst. 3.463. [cited 2020 Mar]. Available from https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/555553 and https:\/\/www.zogenix.com\/wp-content\/uploads\/2018\/12\/3.463_AES-Study-1503-Effectiveness.pdf"},{"key":"cit0051","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1212\/WNL.94.15_supplement.4684","volume":"94","author":"Sullivan J","year":"2020","journal-title":"Neurology"},{"key":"cit0052","unstructured":"Bishop KI, Gioia G, Isquith PK, et al. Improved everyday executive function with fenfluramine HCL oral solution (Fintepla\u00ae): results from a phase 3 study in children and young adults with Dravet syndrome. 72nd American Epilepsy Society Annual Meeting. 2018 Dec. Abst. 2.454. [cited 2020 Mar]. Available from https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/552618 and https:\/\/www.zogenix.com\/wp-content\/uploads\/2018\/11\/2.454-AES-Study-1-BRIEF.pdf"},{"key":"cit0053","unstructured":"Bishop KI, Isquith PK, Gioia G, et al. Profound reduction in seizure frequency (\u226575%) leads to improved everyday executive function: analysis from a phase 3 study of ZX008 (fenfluramine HCL) in children\/young adults with Dravet syndrome. 73rd American Epilepsy Society Annual Meeting. 2019 Dec. Abst. 2.438. Available from [cited 2020 Mar]. https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/2421880 and https:\/\/www.zogenix.com\/wp-content\/uploads\/2019\/12\/01.FINAL-52349-AES-BRIEF-Poster-2019-12-03v4.pdf"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708283370901"},{"key":"cit0055","unstructured":"Lai WW, Pringsheim M, Farfel G, et al. Long-term cardiovascular safety of fenfluramine HCL (Fintepla\u00ae) in the treatment of Dravet syndrome: interim analysis of an open-label safety extension study. 72nd American Epilepsy Society Annual Meeting. 2018 Dec. Abst. 3.453. [cited 2020 Mar]. Available from https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/554593 and https:\/\/www.zogenix.com\/wp-content\/uploads\/2018\/12\/3.453_AES_Study-1503-Long-Term-CV.pdf"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1355781"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.5414\/CP203276"},{"key":"cit0058","unstructured":"Boyd B, Smith S, Farfel GM, et al. A Phase 1, Single-Dose, Open-Label Pharmacokinetic Study to Investigate the Drug-DrugInteraction Potential of ZX008 (Fenfluramine HCl Oral Solution) and Cannabidiol. 73rd American Epilepsy Society Annual Meeting. 2019 Dec [cited 2020 Mar]. Available from: https:\/\/www.zogenix.com\/wp-content\/uploads\/2019\/12\/10_ENCORE-52370-AES-1604-CBD-Poster-2019-12-03v1.pdf"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03495.x"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13407"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03010.x"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2017.09.005"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2014.10.014"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1177\/0883073813487599"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03107.x"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2018.06.023"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03009.x"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.05705.x"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00625"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.12.016"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2017.06.007"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14557"},{"key":"cit0073","unstructured":"ClinicalTrials.gov. NCT03650452. A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of TAK-935 (OV935) as an adjunctive therapy in pediatric patients with developmental and\/or epileptic encephalopathies (ELEKTRA). [cited 2020 Mar]. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03650452"},{"key":"cit0074","unstructured":"ClinicalTrials.gov. NCT03635073. A phase 2, prospective, interventional, open-label, multi-site, extension study to assess the long-term safety and tolerability of TAK-935 (OV935) as adjunctive therapy in patients with rare epilepsy (endymion). [cited 2020 Mar]. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03635073"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31611-2"},{"key":"cit0076","unstructured":"Clinicaltrials.gov. NCT02758626. Ataluren for nonsense mutation in CDKL5 and Dravet syndrome. [cited 2020 Mar]. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02758626"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2013.09.009"},{"key":"cit0078","unstructured":"ClinicalTrials.gov. NCT01607073. Verapamil as therapy for children and young adults with dravet syndrome. [cited 2020 Mar]. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01607073"},{"key":"cit0079","first-page":"669","volume":"140","author":"Griffin A","year":"2017","journal-title":"Brain"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006432"},{"key":"cit0081","unstructured":"ClinicalTrials.gov. NCT04069689. Study of safety and pharmacokinetics of oral doses of EPX-100 in healthy subjects. [cited 2020 Mar]. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04069689"},{"key":"cit0082","unstructured":"Young AN, Tanenhaus A, Belle A, et al. A GABA-selective AAV vector upregulates endogenous SCN1A expression and reverses multiple phenotypes in a mouse model of Dravet syndrome. 73rd American Epilepsy Society Annual Meeting. 2019 Dec. Abst. 3.1. [cited 2020 Mar]. Available from: https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/2421999"},{"key":"cit0083","unstructured":"Miller I, Dlugos D, Segal E, et al. From gene replacement to gene regulation: developing a disease-modifying AAV gene therapy vector for SCN1A\u2013positive (SCN1A+) pediatric epilepsy. 73rd American Epilepsy Society Annual Meeting. 2019 Dec. Abst. 1.091. [cited 2020 Mar]. Available from https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/2421087"},{"key":"cit0084","unstructured":"Isom LL, Chen C, Han Z, et al. Targeted augmentation of nuclear gene output (TANGO) of SCN1A prevents seizures and SUDEP in a mouse model of Dravet syndrome. 72nd American Epilepsy Society Annual Meeting. 2018 Dec. Abst. 1.051. [cited 2020 Mar]. Available from https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/500169"},{"key":"cit0085","unstructured":"Liau G, Christiansen A, Han Z, et al. TANGO oligonucleotides for the treatment of Dravet syndrome: safety, biodistribution, and pharmacology in the non-human primate. 3rd American Epilepsy Society Annual Meeting. 2019 Dec. Abst. 2.195. [cited 2020 Mar]. Available from https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/2421641"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16542"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00708-6"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16546"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2014.03.014"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-176"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.04.039"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000825"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14729"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16474"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1016\/S0387-7604(88)80098-6"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1307454"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb01780.x"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.06.031"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2014.12.028"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12303"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12652"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2020.1801423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:48:06Z","timestamp":1723423686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2020.1801423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,16]]},"references-count":101,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,2]]}},"alternative-id":["10.1080\/14737175.2020.1801423"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2020.1801423","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}